Appendix H: Data analysis

- H.1 Review question 1 data analysisNo additional data analysis performed for this question
- H.2 Review question 2 data analysisNo additional data analysis performed for this question
- H.3 Review question 3 data analysisNo additional data analysis performed for this question
- H.4 Review question 4 data analysisNo additional data analysis performed for this question
- H.5 Review question 5 data analysisNo additional data analysis performed for this question

H.6 Review question 6 data analysis

H.6.1 Self-temperature monitoring for prevention of diabetic foot problems:

Rate of Ulceration

	Experimental Con			ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Armstrong 2007	5	106	14	115	35.7%	0.39 [0.14, 1.04	1]
Lavery 2004	1	41	7	44	17.9%	0.15 [0.02, 1.19	aj
Lavery 2007	17	58	17	56	0.0%	0.97 [0.55, 1.70	0]
Lavery 2007	5	59	17	56	46.4%	0.28 [0.11, 0.71	1
Total (95% CI)		206		215	100.0%	0.30 [0.16, 0.56	s ₁
Total events	11		38				
Heterogeneity: Chi ^z =	0.70, df = 3	2(P = 0)	$.71); I^2 = I$	0%			0.02 0.1 1 10 50
Test for overall effect:	Z = 3.74 (F	P = 0.00	02)				0.02 0.1 1 10 50 Favours experimental Favours control


H.6.2 Pressure customised vs shape customised orthoses for prevention of diabetic foot problems amongst high risk patients:

Rate of Ulceration

	Experime	Contr	ol		Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI	
Bus 2013	33	85	38	86	60.1%	0.88 [0.61, 1.26	5]	
Ulbrecht 2014	6	66	16	64	39.9%	0.36 [0.15, 0.87	7]	
Total (95% CI)		151		150	100.0%	0.62 [0.26, 1.47	1 -	
Total events	39		54					
Heterogeneity: Tau² =				= 0.06)	6	0.02 0.1 1 10 50		
Test for overall effect:	Z = 1.09 (F	r = 0.28)				Favours experimental Favours control	

H.6.3 Therapeutic footwear vs standard care for prevention of diabetic foot problems amongst high risk patients:

Rate of ulceration (different types of footwear vs standard care)




Internal Clinical Guidelines, 2015

H.7 Review question 6 data analysis

H.7.1 ESR testing for osteomyelitis

ERS≥60mm/h							
Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensit
Ertugrul 2009-ERS≥60	22	7	2	15	0.92 [0.73, 0.99]	0.68 [0.45, 0.86]	
Kaleta 2001-ERS≥60	17	1	2	9	0.89 [0.67, 0.99]	0.90 [0.55, 1.00]	
ERS≥65mm/h							0 0.2 0.4 0
Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensit
Kaleta 2001-ERS≥65	17	1	2	9	0.89 [0.67, 0.99]	0.90 [0.55, 1.00]	
Ertugrul 2009-ERS≥65	21	6	3	16	0.88 [0.68, 0.97]	0.73 [0.50, 0.89]	
ERS≥75mm/h							0 0.2 0.4 0
Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensit
Kaleta 2001-ERS≥75	16	О	3	10	0.84 [0.60, 0.97]	1.00 [0.69, 1.00]	
Ertugrul 2009-ERS≥75	19	4	5	18	0.79 [0.58, 0.93]	0.82 [0.60, 0.95]	
ERS≥80mm/h							0 0.2 0.4 (
Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensit
Kaleta 2001-ERS≥80	15	О	4	10	0.79 [0.54, 0.94]	1.00 [0.69, 1.00]	-
Ertugrul 2009-ERS≥80	17	2	7	20	0.71 [0.49, 0.87]	0.91 [0.71, 0.99]	
							0 0.2 0.4 (
ERS≥70mm/h							
Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensit
Kaleta 2001-ERS≥70	17	О	2		0.89 [0.67, 0.99]		
Ertugrul 2009-ERS≥70	20	5	4	17	0.83 [0.63, 0.95]	0.77 [0.55, 0.92]	
ERS>70mm/h							0 0.2 0.4 0
Study TI	P FF	P FN	I TN		Sensitivity	Specificity	Sensit
Malabu 2007-ERS>70 20	o 1	2	20	0.9	91 [0.71, 0.99] 0.9	95 [0.76, 1.00]	
Newman 1991-ERS>70	5 0	13	10	0.2	28 [0.10, 0.53] 1.0	00 [0.69, 1.00]	
ERS>100mm/h							0 0.2 0.4 (
Study	ГР Б	P F	N T	N	Sensitivity	Specificity	Sensit
Newman 1991-ERS>100	6	0 2	0 1	3 0	.23 [0.09, 0.44] 1		. —
	_	_			[, 0]	[,]	0 0.2 0.4 (
2							



H.8 No meta-analysis performed for this question

No additional data analysis performed for this question

H.9 No meta-analysis performed for this question

No additional data analysis performed for this question

H.10 Review question 10 data analysis

Figure 1: Collagen dressings- complete wound healing

	Collagen dre	ssing	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Gottrup 2013	12	23	4	13	10.0%	1.70 [0.69, 4.19]	 -
Veves 2002	51	104	39	84	90.0%	1.06 [0.78, 1.43]	=
Total (95% CI)		127		97	100.0%	1.11 [0.83, 1.47]	+
Total events	63		43				
Heterogeneity: Tau² =			1 (P = 0.3)	3); l² =		0.01 0.1 1 10 100	
Test for overall effect:	Z = 0.70 (P = 0)	.48)				Favo	ours Collagen dressing Favours control

Figure 2: Collagen dressings- Adverse events

	Collagen dressing			ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
Gottrup 2013	0	23	5	13	33.5%	0.05 [0.00, 0.89]	
Veves 2002	25	104	35	84	66.5%	0.58 [0.38, 0.88]	
Total (95% CI)		127		97	100.0%	0.26 [0.03, 2.56]	
Total events	25		40				
Heterogeneity: Tau² =	2.00; Chi ² = 2.5	89, df = 1	1 (P = 0.0	19); I² =		0.01 0.1 1 10 100	
Test for overall effect:	Z=1.16 (P=0	.25)				Favo	ours Collagen dressing Favours control

Figure 3: Irremovable versus removable offloading devices- Wound healing TCC versus Removable cast walker

	TCC	;	RCV	V		Risk Ratio (Non-event)		Risk Ratio (Non-event)	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Random, 95% CI	
Armstrong 2001	17	19	13	20	11.9%	0.30 [0.07, 1.27]			
Armstrong 2005	19	23	14	27	26.2%	0.36 [0.14, 0.96]			
Caravaggi 2007	24	29	23	29	21.7%	0.83 [0.29, 2.43]			
Faglia 2010	17	23	16	22	26.4%	0.96 [0.36, 2.52]			
Gutekunst 2011	9	11	5	12	13.8%	0.31 [0.08, 1.19]			
Total (95% CI)		105		110	100.0%	0.54 [0.33, 0.88]		•	
Total events	86		71						
Heterogeneity: Tau² =	0.00; Chi	$i^2 = 3.93$	3, df = 4 (P = 0.4	2); I² = 0%	6	0.01	01 1 10	100
Test for overall effect:	Z = 2.45 ((P = 0.0)	11)		0.01	Favours TCC Favours RCW	100		

Figure 4: Irremovable versus removable offloading devices- Mean healing time (days) TCC versus Removable cast walker

		TCC		F	RCW			Std. Mean Difference	Std. Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI			
Armstrong 2001	33.5	5.9	19	50.4	7.2	20	32.3%	-2.51 [-3.37, -1.65]	-			
Armstrong 2005	41.6	18.7	23	58	15.2	27	35.0%	-0.96 [-1.54, -0.37]	-			
Gutekunst 2011	95	61	11	94	64	12	32.7%	0.02 [-0.80, 0.83]	†			
Total (95% CI)			53			59	100.0%	-1.14 [-2.43, 0.15]	•			
Heterogeneity: Tau² =	Heterogeneity: Tau ² = 1.14; Chi ² = 17.66, df = 2 (P = 0.0001); I ² = 89%											
Test for overall effect:	Z = 1.74	(P = 0	0.08)						-10 -5 0 5 10 Favours TCC Favours RCW			

Figure 5: Irremovable versus removable offloading devices- Wound healing TCC versus Removable footwear

	Cas	Footw	еаг		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Caravaggi 2010	13	26	5	24	52.1%	2.40 [1.01, 5.73]	
Van de Weg 2008	6	23	6	20	47.9%	0.87 [0.33, 2.27]	
Total (95% CI)		49		44	100.0%	1.48 [0.55, 3.99]	-
Total events	19		11				
Heterogeneity: Tau² =		1%	0.01 0.1 1 10 100				
Test for overall effect:	Z = 0.77	(P = 0.4)	14)				Favours Cast Favours Footwear

Figure 6: Irremovable versus Irremovable offloading devices- Wound healing TCC versus iTCC

	Ехрегіт	Contr	rol		Risk Ratio	Risk Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI				
Katz 2005	15	20	17	21	29.8%	0.93 [0.67, 1.29]	+				
Piaggesi 2007	19	20	17	20	70.2%	1.12 [0.91, 1.38]	•				
Total (95% CI)		40		41	100.0%	1.06 [0.88, 1.27]	•				
Total events	34		34								
Heterogeneity: Tau² =	Heterogeneity: Tau ² = 0.00; Chi ² = 1.03, df = 1 (P = 0.31); I ² = 3%										
Test for overall effect:	Z = 0.60 (F	P = 0.55)				0.01 0.1 1 10 100 Favours TCC Favours iTCC				

Figure 7: Irremovable versus Irremovable offloading devices- adverse events TCC versus iTCC

	Experime	Contr	ol		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl			
Katz 2005	13	20	8	21	70.7%	1.71 [0.91, 3.21]	+			
Piaggesi 2007	4	20	5	20	29.3%	0.80 [0.25, 2.55]				
Total (95% CI)		40		41	100.0%	1.37 [0.69, 2.72]	•			
Total events	17		13							
Heterogeneity: Tau ² = 0.07; Chi ² = 1.31, df = 1 (P = 0.25); I ² = 23% $0.01 0.1 1$										
Test for overall effect	:Z=0.89 (F	P = 0.37	")				0.01 0.1 1 10 100 Favours TCC Favours iTCC			


H.11 Review question 11 data analysis

No additional data analysis performed for this question


H.12 Review question 12 data analysis

H.12.1 Cure rate

H.12.1.1 Growth factor and growth factor derived treatments




H.12.1.2 Dermal or skin substitutes




Internal Clinical Guidelines, 2015


H.12.1.3 Hyperbaric oxygen therapy




H.12.1.4 ANGIPARS herbal



H.12.1.5 Promogran




H.12.1.6 Negative pressure wound therapy



Test for subgroup differences: Not applicable


H.12.2 Amputation rate

H.12.2.1 Dermal or skin substitutes



Internal Clinical Guidelines, 2015


H.12.2.2 Hyperbaric oxygen therapy




Test for subgroup differences: Not applicable

H.12.3 Adverse events rate


H.12.3.1 Growth factor and growth factor derived treatments



H.12.3.2 Dermal or skin substitutes




H.12.3.3 Promogran



Test for subgroup differences: Not applicable


H.12.3.4 Negative pressure wound therapy



Test for subgroup differences: Not applicable


H.12.4 Infection rate

H.12.4.1 Growth factor and growth factor derived treatments




Test for subgroup differences: $Chi^2 = 0.00$, df = 1 (P = 0.95), $I^2 = 0\%$

H.12.4.2 Dermal or skin substitutes



Test for subgroup differences: Chi² = 2.62, df = 4 (P = 0.62), I^2 = 0%

H.12.4.3 Promogran



Test for subgroup differences: Not applicable

H.13 Review question 13 data analysisNo additional data analysis performed for this question

H.14 Review question 14 data analysisNo additional data analysis performed for this question

H.15 Review question 15 data analysisNo additional data analysis performed for this question

H.16 Review question 16 data analysisNo additional data analysis performed for this question